OSE IMMUNOTHERAPEUTICS |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 8.1 EUR | -3.11% |
|
+9.31% | +89.25% |
| May. 22 | OSE, Boehringer Ingelheim Expand Partnership for Immuno-oncology Programs | MT |
| May. 22 | OSE: agreement extended with Boehringer Ingelheim, share price rises | CF |
"Total Return" performance includes dividend payments over the period, as if they were reinvested at 100%.
End-of-day quotes
End-of-day quotes
Compared values
| Sector | Change | 5d. change | 1st Jan change | 1-year change | 5-years change | Capi. | ST | MT | LT | ||
|---|---|---|---|---|---|---|---|---|---|---|---|
| OSE IMMUNOTHERAPEUTICS | Other Biotechnology & Medical Research | -3.11% | +9.31% | +89.25% | +121.61% | +116.58% | 191M |  | | |
Technical Rankings Surperformance
- Stock Market
- Equities
- OSE Stock
- Charts OSE Immunotherapeutics
- Comparison Chart
